These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
85 related items for PubMed ID: 20156481
1. Mycobacterium vaccae vaccine to prevent tuberculosis in high risk people: a meta-analysis. Yang XY, Chen QF, Cui XH, Yu Y, Li YP. J Infect; 2010 May; 60(5):320-30. PubMed ID: 20156481 [Abstract] [Full Text] [Related]
2. Preventive effects of Mycobacterium vaccae on HIV-associated tuberculosis: a systematic review. Chen Q, Yang X, Li Y, He X, Ma X, Ma L, Guo Z, Li L. J Evid Based Med; 2011 May; 4(2):122-9. PubMed ID: 23672702 [Abstract] [Full Text] [Related]
3. Rifampicin plus pyrazinamide versus isoniazid for treating latent tuberculosis infection: a meta-analysis. Gao XF, Wang L, Liu GJ, Wen J, Sun X, Xie Y, Li YP. Int J Tuberc Lung Dis; 2006 Oct; 10(10):1080-90. PubMed ID: 17044199 [Abstract] [Full Text] [Related]
4. Mycobacterium vaccae as adjuvant therapy to anti-tuberculosis chemotherapy in never-treated tuberculosis patients: a meta-analysis. Yang XY, Chen QF, Li YP, Wu SM. PLoS One; 2011 Oct; 6(9):e23826. PubMed ID: 21909406 [Abstract] [Full Text] [Related]
5. Immunogenicity of an inactivated mycobacterial vaccine for the prevention of HIV-associated tuberculosis: a randomized, controlled trial. Vuola JM, Ristola MA, Cole B, Järviluoma A, Tvaroha S, Rönkkö T, Rautio O, Arbeit RD, von Reyn CF. AIDS; 2003 Nov 07; 17(16):2351-5. PubMed ID: 14571187 [Abstract] [Full Text] [Related]
8. Tuberculosis vaccination versus isoniazid preventive therapy: a decision analysis to determine the preferred strategy of tuberculosis prevention in HIV-infected adults in the developing world. Sterling TR, Brehm WT, Moore RD, Chaisson RE. Int J Tuberc Lung Dis; 1999 Mar 07; 3(3):248-54. PubMed ID: 10094327 [Abstract] [Full Text] [Related]
12. Efficacy of Mycobacterium vaccae immunotherapy for patients with tuberculosis: A systematic review and meta-analysis. Huang CY, Hsieh WY. Hum Vaccin Immunother; 2017 Sep 02; 13(9):1960-1971. PubMed ID: 28604170 [Abstract] [Full Text] [Related]
13. The Systematic Review and Meta-Analysis on the Immunogenicity and Safety of the Tuberculosis Subunit Vaccines M72/AS01E and MVA85A. Ullah I, Bibi S, Ul Haq I, Safia, Ullah K, Ge L, Shi X, Bin M, Niu H, Tian J, Zhu B. Front Immunol; 2020 Sep 02; 11():1806. PubMed ID: 33133057 [Abstract] [Full Text] [Related]
14. Immunogenicity and Safety of the M72/AS01E Candidate Vaccine Against Tuberculosis: A Meta-Analysis. Ji Z, Jian M, Chen T, Luo L, Li L, Dai X, Bai R, Ding Z, Bi Y, Wen S, Zhou G, Abi ME, Liu A, Bao F. Front Immunol; 2019 Sep 02; 10():2089. PubMed ID: 31552037 [Abstract] [Full Text] [Related]
19. Cellular immune responses to mycobacteria in healthy and human immunodeficiency virus-positive subjects in the United States after a five-dose schedule of Mycobacterium vaccae vaccine. von Reyn CF, Marsh BJ, Waddell R, Lein AD, Tvaroha S, Morin P, Modlin JF. Clin Infect Dis; 1998 Dec 02; 27(6):1517-20. PubMed ID: 9868670 [Abstract] [Full Text] [Related]